What is Excision BioTherapeutics?
Excision BioTherapeutics is at the forefront of developing transformative gene editing solutions, specifically utilizing CRISPR technology to address a range of viral infectious diseases. The company's core mission is to provide functional cures by precisely excising viral DNA from host cells. Excision has demonstrated groundbreaking success, including the first functional cure for HIV in animal models, showcasing the potential of its proprietary technologies and intellectual property, which originated from research at Temple University and U.C. Berkeley. Based in San Francisco, California, Excision BioTherapeutics operates within the highly competitive and rapidly evolving biotechnology sector, focusing on unmet medical needs in virology.
How much funding has Excision BioTherapeutics raised?
Excision BioTherapeutics has raised a total of $70M across 2 funding rounds:
Angel/Seed
$10M
Other Financing Round
$60M
Angel/Seed (2017): $10M with participation from ARTIS Ventures
Other Financing Round (2021): $60M led by Anzu Partners, Adjuvant Capital, Norwest Venture Partners, GreatPoint Energy, ARTIS Ventures, Cota Capital, Loreda Holdings, WRVI Capital, IndusAge Advisors, and Olive Tree Capital
Key Investors in Excision BioTherapeutics
Anzu Partners
Anzu Partners is an investment firm focused on breakthrough technologies in clean tech, industrial, and life sciences sectors, managing $1 billion in assets. The company collaborates with a diverse team of investors, operators, consultants, scientists, and engineers to support founders in bringing innovative solutions to market.
ARTIS Ventures
Artis Ventures is a dedicated venture capital fund focused on Tech Bio+Health, investing in innovative data-driven life sciences companies that aim to enhance human health and wellness. The company aims to create a significant global impact through investments in scalable medical technologies that leverage AI and engineering to develop personalized therapeutics and efficient drug discovery.
Norwest Venture Partners
Founded in 1961, Norwest Venture Partners is a global, multi-stage venture capital and growth equity investment firm. The company is headquartered in Palo Alto, California with offices in India and Israel.
What's next for Excision BioTherapeutics?
With the recent influx of major strategic capital, Excision BioTherapeutics is poised to accelerate its research and development pipeline, potentially advancing its lead therapeutic candidates toward clinical trials. The company's focus on excising viral genomes represents a novel therapeutic strategy that could redefine treatment paradigms for diseases like HIV. Future growth will likely involve further validation of its CRISPR-based platform, expansion of its intellectual property portfolio, and strategic partnerships to navigate the complex regulatory and commercialization pathways inherent in the biotechnology industry. The sustained investment indicates a strong belief in the company's long-term vision and its potential to achieve significant milestones in curative viral therapies.
See full Excision BioTherapeutics company page
